In 2004, Turner, et al. coined the term “BRCAness” to describe patients who do not have a pathogenic germline variant in BRCA1 or BRCA2 but who have developed a tumor with an impaired ability to perform HR [31]. This evidence concerns the gene BRCA1 and neoplasm.